What type of study is this?

This is a Systematic Review study (also classified as: Meta-Analysis).

September 16, 2025Frontiers in PharmacologyOpen Access

Efficacy and safety of fruquintinib in the treatment of colorectal cancer: a systematic review and meta-analysis of studies in China

View Full Paper

Ask AI

Bookmark

Fruquintinib significantly improved overall survival in colorectal cancer patients, enhancing treatment outcomes.
Results indicated a notable progression-free survival increase, with a hazard ratio of 0.44, highlighting efficacy.
The systematic review analyzed data from 11 studies across 2,367 patients, ensuring a comprehensive evaluation.
Further investigation is recommended due to potential instability in hypertension risk observed in sensitivity analysis.

No takes yet. Share an insight, caveat, or question.

Systematic review demonstrates improved overall and progression-free survival in colorectal cancer, suggesting it is a safe option.

Yuan et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark